These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 38534371)
1. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D Cells; 2024 Mar; 13(6):. PubMed ID: 38534371 [TBL] [Abstract][Full Text] [Related]
2. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D bioRxiv; 2024 Mar; ():. PubMed ID: 38464204 [TBL] [Abstract][Full Text] [Related]
3. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related]
4. A selective BCL-X Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461 [TBL] [Abstract][Full Text] [Related]
5. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252 [TBL] [Abstract][Full Text] [Related]
6. Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. Lochmann TL; Floros KV; Naseri M; Powell KM; Cook W; March RJ; Stein GT; Greninger P; Maves YK; Saunders LR; Dylla SJ; Costa C; Boikos SA; Leverson JD; Souers AJ; Krystal GW; Harada H; Benes CH; Faber AC Clin Cancer Res; 2018 Jan; 24(2):360-369. PubMed ID: 29118061 [No Abstract] [Full Text] [Related]
7. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy. Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472 [TBL] [Abstract][Full Text] [Related]
8. Bcl-2/Bcl-xL inhibitor navitoclax increases the antitumor effect of Chk1 inhibitor prexasertib by inducing apoptosis in pancreatic cancer cells via inhibition of Bcl-xL but not Bcl-2. Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Hamamoto T; Masuda Y Mol Cell Biochem; 2020 Sep; 472(1-2):187-198. PubMed ID: 32567031 [TBL] [Abstract][Full Text] [Related]
9. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766 [TBL] [Abstract][Full Text] [Related]
10. Co-targeting BCL-X Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105 [TBL] [Abstract][Full Text] [Related]
11. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706 [TBL] [Abstract][Full Text] [Related]
12. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723 [TBL] [Abstract][Full Text] [Related]
13. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
14. AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x Balachander SB; Criscione SW; Byth KF; Cidado J; Adam A; Lewis P; Macintyre T; Wen S; Lawson D; Burke K; Lubinski T; Tyner JW; Kurtz SE; McWeeney SK; Varnes J; Diebold RB; Gero T; Ioannidis S; Hennessy EJ; McCoull W; Saeh JC; Tabatabai A; Tavana O; Su N; Schuller A; Garnett MJ; Jaaks P; Coker EA; Gregory GP; Newbold A; Johnstone RW; Gangl E; Wild M; Zinda M; Secrist JP; Davies BR; Fawell SE; Gibbons FD Clin Cancer Res; 2020 Dec; 26(24):6535-6549. PubMed ID: 32988967 [TBL] [Abstract][Full Text] [Related]
15. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768 [TBL] [Abstract][Full Text] [Related]
16. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266 [TBL] [Abstract][Full Text] [Related]
17. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer. Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936 [TBL] [Abstract][Full Text] [Related]